Top stories from TTO's February newsletter:
Orphan Technologies to Develop New Treatment for Life-Threatening Metabolic Disorder from CU
The University of Colorado has signed exclusive, worldwide licensing and collaboration agreements with rare-disease research-and-development firm Orphan Technologies Ltd to develop an enzyme replacement therapy for Cystathionine Beta-Synthase (CBS) -deficient homocystinuria, a rare, inherited metabolic disease that is often fatal at a young age. The collaboration was initiated in 2010 and includes sponsored-research funding by OT to continue development of the treatment approach pioneered by Jan P. Kraus, a professor of pediatrics at the CU School of Medicine. Orphan Technologies plans to begin first-in-human trials in 2014.
F5 Networks Acquires CU-Boulder Networking Startup LineRate Systems
F5 Networks has acquired Louisville-based LineRate Systems, a CU startup that's developing technologies around what's called software-defined networking, a computer networking approach that allows network behavior to be governed by high-level software programming, rather than by the low-level configurations of the network's devices, making networks easier to configure, manage, troubleshoot, and debug. The company was founded in 2008 by CU-Boulder researchers John Giacomoni and Manish Vachharajani. In 2008 LineRate received early-stage funding from TTO to support the development of its technology through TTO's Proof-of Concept Investment (POCi) program.
TTO Signs Pact to Help Convert Biotech Research Into Bucks
FDA Approves Sobi's Kineret® to Treat NOMID
GlobeImmune Begins Phase 1a Clinical Trial of its Chronic HBV Vaccine
Read the full newsletter, or sign up to receive a monthly email update.